Introduction
Gynecomastia develops when the normal balance between estrogenic and androgenic effects in male breast tissue is disrupted, allowing glandular tissue to grow. In practical terms, this means that the breast tissue is being stimulated more strongly by estrogen, or less strongly restrained by testosterone and related androgens, than it should be. The condition is not caused by a single mechanism. It can arise from hormonal shifts, medication effects, systemic disease, developmental changes, or exposure to substances that alter endocrine function. Understanding gynecomastia requires looking at how the body normally regulates breast tissue and how that regulation becomes altered.
The main causes fall into several broad categories: physiologic hormonal changes, medications and substances, underlying medical disorders, environmental or lifestyle influences, and inherited or developmental factors. In many people, more than one factor is present at the same time, which makes the condition more likely to appear or persist.
Biological Mechanisms Behind the Condition
Male breast tissue is not inert. It contains ductal structures and stromal tissue that remain responsive to sex hormones throughout life. Under normal circumstances, androgens such as testosterone and dihydrotestosterone suppress breast gland growth, while estrogens promote it. In healthy males, the relative dominance of androgens keeps glandular breast tissue small.
Gynecomastia develops when this hormonal balance shifts toward estrogenic stimulation. That shift can occur in several ways. The most direct is an increase in estrogen levels. Another is a fall in testosterone production, which removes the inhibitory effect on breast tissue. A third mechanism is increased conversion of androgens into estrogens through the enzyme aromatase, which is active in adipose tissue and some tumors. Some conditions also raise the sensitivity of breast tissue to circulating estrogens, making normal hormone levels biologically more potent.
The tissue changes that follow are usually glandular rather than simply fatty. Estrogen stimulates ductal proliferation, stromal expansion, and tissue remodeling. In early stages, the process may be reversible if the hormonal imbalance resolves. Over time, however, the tissue can become more fibrotic and less responsive to reversal. This is why the timing and duration of the underlying hormonal disruption matter.
Primary Causes of Gynecomastia
Pubertal hormonal fluctuation is one of the most common causes. During puberty, testosterone production rises, but not always in a perfectly synchronized way. In some adolescent boys, estradiol temporarily exceeds the local anti-estrogenic effect of androgens within breast tissue. This transient imbalance can produce palpable glandular enlargement. In many cases, the body later reestablishes a more stable hormone ratio and the tissue regresses. The mechanism is developmental rather than pathological, but the biological basis is the same: a temporary excess of estrogenic signaling relative to androgenic signaling.
Age-related decline in testosterone is another major cause. As men age, total and free testosterone often decrease, while body fat may increase and aromatase activity may rise. Both changes favor estrogenic influence. Lower androgen levels reduce suppression of breast tissue, and greater conversion of androgens to estrogens can amplify the signal that drives glandular growth. This helps explain why gynecomastia is more common in older adults than in younger men.
Medications are a frequent and important cause because many drugs alter hormone synthesis, metabolism, binding, or receptor activity. Antiandrogens, some prostate cancer therapies, certain anabolic steroid regimens, spironolactone, ketoconazole, cimetidine, some antipsychotics, and some antidepressants can all contribute through different pathways. A drug may suppress testosterone production, block androgen receptors, raise prolactin, or increase estrogen effect indirectly. The outcome is similar: the breast tissue experiences a relative increase in estrogenic stimulation. Because medication-induced gynecomastia depends on a specific pharmacologic mechanism, it can appear after dose changes, prolonged use, or withdrawal from exogenous androgens that had been suppressing the body’s own hormone production.
Substance use can also contribute. Alcohol, marijuana, opioids, and anabolic steroids are commonly discussed because they can interfere with endocrine regulation. Alcohol can impair liver function and alter sex hormone metabolism. Opioids can suppress the hypothalamic-pituitary-gonadal axis, lowering testosterone. Anabolic steroids may initially seem androgenic, but they can suppress endogenous testosterone and then leave estrogenic effects relatively unopposed when use changes or stops. The biology is not simply about toxicity; it is about how these substances shift hormone production, clearance, and receptor signaling.
Liver disease is a classic cause because the liver metabolizes estrogens and many sex hormone-binding proteins. When liver function is impaired, estrogen clearance may fall and the ratio of free hormones may change. Cirrhosis is particularly associated with gynecomastia because it combines reduced hormone metabolism, altered binding protein production, and often increased peripheral aromatization. The result is a systemic endocrine state that favors breast tissue growth.
Contributing Risk Factors
Genetic influences can increase susceptibility by affecting hormone production, receptor sensitivity, or enzyme activity. Variations in aromatase expression, androgen receptor function, or enzymes involved in steroid synthesis can tilt the balance toward estrogenic effects. Inherited differences may not cause gynecomastia on their own, but they can lower the threshold at which another trigger, such as puberty, illness, or a medication, becomes clinically visible.
Body fat and metabolic state are important risk factors because adipose tissue is a biologically active endocrine organ. Fat cells express aromatase, which converts androgens into estrogens. Higher body fat can therefore raise local and systemic estrogen production. Obesity also tends to reduce testosterone through multiple mechanisms, including insulin resistance, inflammation, and changes in sex hormone-binding globulin. These effects work together to create a hormonal environment that favors breast tissue proliferation.
Environmental exposures may contribute when they affect endocrine signaling. Some chemicals act as endocrine disruptors or weak estrogen mimics, including certain industrial compounds, pesticides, and plastic-associated chemicals. Their impact is usually small compared with major medical causes, but chronic exposure may influence hormone balance, especially in people already vulnerable because of age, obesity, or liver dysfunction. The biological effect comes from altered receptor signaling, enzyme interference, or changes in hormone metabolism.
Hormonal shifts during life stages also increase risk. Newborns may show transient gynecomastia due to maternal estrogen exposure in utero. During puberty, the endocrine system is still stabilizing, so temporary imbalances are common. Later in life, declining gonadal function and comorbid illness can recreate the same relative excess of estrogenic effect. These are not separate diseases so much as predictable windows when hormone regulation is less stable.
Infections and systemic inflammation can act indirectly. Severe illness may suppress gonadal hormone production, alter liver function, or disrupt hypothalamic signaling. Although infection is less often a direct cause than hormonal disease or medication exposure, it can trigger the same downstream endocrine pattern: reduced testosterone activity relative to estrogenic influence.
How Multiple Factors May Interact
Gynecomastia often reflects overlapping influences rather than a single cause. For example, an older man with obesity may have lower testosterone, higher aromatase activity, and reduced hepatic clearance of estrogens. Any one of those factors might be modest on its own, but together they create a stronger biological push toward glandular breast growth. Similarly, a medication that mildly suppresses androgen production may not cause gynecomastia in a lean young person, yet the same drug could trigger it in someone with liver disease or borderline hypogonadism.
These interactions matter because endocrine systems are interconnected. The hypothalamus, pituitary gland, testes, liver, adrenal glands, and adipose tissue all contribute to sex hormone balance. A disturbance in one system can alter multiple others. For instance, reduced testosterone can lead to increased fat accumulation, which then increases aromatase activity, which further increases estrogen production. This creates a reinforcing cycle that helps explain why gynecomastia may persist once established.
Variations in Causes Between Individuals
The cause of gynecomastia differs from person to person because the same hormone signal does not produce the same tissue response in every body. Genetics influences the baseline sensitivity of breast tissue and the efficiency of hormone metabolism. Age changes the hormonal set point, so the same exposure may have different effects in adolescence, adulthood, and older age. Health status also matters because liver disease, renal disease, endocrine disorders, and obesity alter the internal hormone environment in different ways.
Environmental exposure can further shape risk by changing cumulative endocrine load over time. A person with low baseline risk may never develop gynecomastia despite a mild estrogenic exposure, whereas someone with multiple predisposing factors may develop it from the same exposure. This variability reflects biological context: gynecomastia emerges when enough influences converge to shift breast tissue from androgen-dominant restraint to estrogen-dominant stimulation.
Conditions or Disorders That Can Lead to Gynecomastia
Hypogonadism is a major underlying disorder because it lowers testosterone production. This may result from testicular failure, pituitary disease, hypothalamic dysfunction, genetic disorders, or damage from infection or trauma. When testosterone falls, estrogenic effects become relatively stronger even if estrogen levels are unchanged. The breast tissue responds to that altered ratio by enlarging.
Hyperthyroidism can contribute by increasing sex hormone-binding globulin and altering peripheral hormone metabolism. The net effect may increase the biologically active estrogen-to-androgen balance. Thyroid hormone excess also affects liver protein synthesis and can change how circulating sex hormones are distributed.
Chronic kidney disease may lead to gynecomastia through multiple mechanisms, including impaired hormone metabolism, altered gonadotropin signaling, and reduced testosterone production. Uremia can also disrupt endocrine homeostasis more broadly, creating conditions in which breast tissue becomes more responsive to estrogenic influence.
Testicular disorders and tumors may raise gynecomastia risk either by lowering testosterone or by producing hormones directly. Some testicular tumors secrete hCG, which can stimulate hormone pathways that increase estrogen production. Others damage testicular tissue and reduce androgen output. In both cases, the critical shift is again the hormonal ratio affecting breast tissue.
Adrenal and estrogen-producing tumors can also be involved. Because the adrenal glands and some neoplasms can produce steroid precursors or estrogens, they may create a systemic environment with excessive estrogenic activity. Although less common than medication-related or developmental causes, these disorders are important because they can produce pronounced and persistent gynecomastia.
Conclusion
Gynecomastia develops when breast tissue is exposed to a relative excess of estrogenic stimulation, a relative deficiency of androgenic restraint, or both. The most important causes include pubertal hormonal fluctuation, aging-related testosterone decline, medications, substance use, liver disease, obesity, and disorders of the testes, pituitary, thyroid, kidneys, or adrenal glands. Genetic susceptibility, environmental endocrine disruptors, and systemic illness can increase the likelihood that these triggers will produce visible tissue growth.
What unites the different causes is the same biological principle: normal male breast tissue is hormone responsive, and it enlarges when the balance of sex hormone signaling shifts. Recognizing the underlying mechanisms explains why the condition appears in some people and not others, why it may be temporary in one setting and persistent in another, and why its causes are often multifactorial rather than singular.